肝细胞癌阿替利珠单抗联合贝伐珠单抗治疗中RECIST 1.1与mRECIST的影像学疗效评估
该回顾性研究纳入207例接受一线阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者,由两名放射科医生独立采用RECIST 1.1和mRECIST评估疗效。mRECIST识别出更多缓解者(54.6% vs. 16.9%),RECIST 1.1的读者间一致性更高(加权kappa 0.89 vs. 0.79),且基于RECIST 1.1的模型对总生存的预后区分能力略优(C-index 0.68/0.75 vs. 0.65/0.70)。结论认为RECIST 1.1可重复性和预后价值更佳,但mRECIST仍可作为生物学肿瘤缓解标志物。
要点
- RECIST 1.1读者间一致性优于mRECIST(加权kappa 0.89 vs. 0.79)。
- mRECIST识别缓解者比例更高(54.6% vs. 16.9%)。
- RECIST 1.1模型对OS的C-index略高于mRECIST。
核心结论
- RECIST 1.1在评估肝细胞癌患者接受一线阿替利珠单抗联合贝伐珠单抗治疗的疗效时,具有更高的可重复性和略优的预后价值。
- mRECIST虽预后区分能力稍低,但仍可作为生物学肿瘤缓解标志物使用。
研究设计与样本
- 回顾性研究,纳入2020年6月至2022年12月单中心接受一线阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者207例(171例男性,中位年龄63岁)。
- 纳入标准为至少有一个富血供肝靶病灶;两名放射科医生独立采用RECIST 1.1和mRECIST评估治疗反应。
- 采用Cohen kappa系数评估读者间一致性,采用时间依赖Cox回归(影像学缓解和进展作为时变协变量)分析预后,采用Harrell C-index评估预后区分能力。
诊断标准与关键数值
- mRECIST识别缓解者比例为54.6%,RECIST 1.1为16.9%。
- RECIST 1.1的读者间一致性加权kappa为0.89(优秀),mRECIST为0.79(良好)。
- mRECIST观察到分离反应的比例显著高于RECIST 1.1(14.0% vs. 4.3%,P < 0.001)。
- 基于RECIST 1.1的模型C-index:缓解0.68、进展0.75;基于mRECIST的模型:缓解0.65、进展0.70。
临床应用与阅片要点
- 在肝细胞癌免疫联合抗血管生成治疗疗效评估中,RECIST 1.1可作为主要报告标准,因其读者间一致性高且预后区分能力略优。
- mRECIST可识别更多缓解者,但需注意其读者间一致性稍低且分离反应率更高,报告时应结合临床。
局限性
- 本研究为单中心回顾性设计,可能存在选择偏倚。
- 中位随访时间较短(10.7个月),长期预后价值需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Evidence remains limited regarding whether Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) or modified RECIST (mRECIST) more reliably assesses treatment response in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (Atezo/Bev). This study aimed to evaluate response patterns based on RECIST 1.1 and mRECIST, analyze inter-reader agreement, and assess their prognostic value for overall survival (OS) in patients with HCC receiving first-line Atezo/Bev.
MATERIALS AND METHODS: This retrospective study included patients with HCC treated with first-line Atezo/Bev between June 2020 and December 2022 at a tertiary center. Patients with at least one hypervascular hepatic target lesion were eligible. Two radiologists independently assessed treatment responses using RECIST 1.1 and mRECIST. Inter-reader agreement was evaluated using Cohen's kappa coefficient. Time-dependent Cox regression analysis was performed, with radiologic response and progression treated as time-varying covariates. Prognostic discrimination was evaluated using Harrell's concordance index (C-index).
RESULTS: A total of 207 patients were included (171 men; median age, 63 years; median follow-up, 10.7 months [range, 0.8-46.4 months]; median OS, 10.7 months [95% confidence interval, 9.2-12.8 months]). mRECIST identified more responders than RECIST 1.1 (54.6% vs. 16.9%). RECIST 1.1 demonstrated excellent inter-reader agreement, whereas mRECIST showed substantial agreement (weighted kappa, 0.89 vs. 0.79). A significantly higher rate of dissociated responses was observed with mRECIST than with RECIST 1.1 (14.0% vs. 4.3%, P < 0.001). Both RECIST 1.1- and mRECIST-based responses and progression were independently associated with OS. Models incorporating RECIST 1.1 demonstrated slightly higher C-index values than those incorporating mRECIST (RECIST 1.1: 0.68 for response and 0.75 for progression; mRECIST: 0.65 and 0.70, respectively).
CONCLUSION: RECIST 1.1 is more reproducible and prognostically valuable for guiding treatment decisions in patients with HCC receiving first-line Atezo/Bev. However, this does not invalidate the use of mRECIST as a biological tumor response marker.
引用
- Jeong B, Park HJ, Choi WM, et al. Radiologic Response Assessment With RECIST 1.1 and mRECIST in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Korean J Radiol. 2026. PMID: 42062227. doi:10.3348/kjr.2025.1849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。